Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827366 | 0.97 | TSHR (0.48) | TSHRCYP2C9CYP2C19EPHX2SMN1; SMN2 | |
| SCHEMBL4819462 | 0.94 | TSHR (0.48) | TSHRCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL4822150 | 0.90 | EPHX2 (0.46) | TSHRCYP2C9CYP2C19EPHX2F2 | |
| SCHEMBL4826990 | 0.89 | TSHR (0.49) | TSHRCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL4827358 | 0.87 | F2 (0.44) | TSHRCYP2C9CYP2C19EPHX2F2 | |
| SCHEMBL4819456 | 0.83 | TAAR1 (0.48) | EPHX2SMN1; SMN2F2TAAR1 | |
| SCHEMBL4826884 | 0.82 | TSHR (0.46) | TSHRCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL4824861 | 0.82 | TSHR (0.46) | TSHRCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL4894630 | 0.78 | CTSL (0.42) | TSHRCYP2C9CYP2C19 | |
| SCHEMBL4826986 | 0.78 | F2 (0.42) | TSHRCYP2C9CYP2C19F2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | TSHR 2926/4885CYP2C9 1781/4885CYP2C19 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.